• Citer

Methodology for clinical genotyping of CYP2D6 and CYP2C19

par Carvalho Henriques, Beatriz;Buchner, Avery;Hu, Xiuying;Wang, Yabing;Yavorskyy, Vasyl;Wallace, Keanna;Dong, Rachael;Martens, Kristina;Carr, Michael M.S.;Behroozi Asl, Bahareh;Hague, Joshua;Sivapalan, Sudhakar;Maier, Wolfgang;Dernovsek, Mojca Zvezdana;Henigsberg, Neven;Hauser, Joanna Wiktoria;Souery, Daniel ;Cattaneo, Annamaria;Mors, Ole;Rietschel, M.;Pfeffer, Gerald;Hume, Stacey;Aitchison, Katherine
Référence Translational Psychiatry, 11, 1, 596
Publication Publié, 2021-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross-validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long-range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm.